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The hemorphins are opioid active peptides, which are enzymatically released from the beta-chain of hemoglobin. In this paper we report an inhibi- 
tory effect of these peptides on angiotensin converting enzyme (ACE) activity, known to be involved in blood pressure regulation. The hemorphins 
were found to be quite stable in tissue extracts containing ACE, and their importance as naturally occurring ACE inhibitors is discussed. 
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1. INTRODUCTION 
The hemorphins are hemoglobin-derived peptides 
with affinity for opioid receptors [1,2]. They were 
originally isolated from enzymatically treated bovine 
blood [2] and the smallest active fragment Tyr-Pro-Trp- 
Thr (hemorphin-4) represents fragment 34-37 of the 
beta-chain of bovine hemoglobin. The same fragment 
occurs in the human protein, at the position 35-38 of 
the beta-, gamma-, delta-, or epsilon- chain [2]. The N- 
terminal, Tyr-Pro, is also found in the beta-casomor- 
phins, which have previously been shown to inhibit 
ACE activity [3]. Recently, an opioid active fragment 
of hemoglobin was isolated from the human pituitary 
gland [4]. This peptide (LVV-hemorphin-6) corre- 
sponds to the sequence at position 32-40 of the beta- 
chain of the human entity. Its physiological significance 
is unknown, so far, but since it is found in large 
amounts in the pituitary, it is likely to also occur in the 
circulation. 
Angiotensin converting enzyme (ACE) is a peptidyl 
dipeptide hydrolase (EC 3.4.15.1), which liberates the 
octapeptide angiotensin II from the decapeptide angio- 
tensin I, by cleaving off the C-terminal dipeptide His- 
Leu [5]. Moreover, it inactivates the vasodilator brady- 
kinin, by sequentially removing its 2 C-terminaf dipep- 
tides [6]. Angiotcnsin II is a strong vasoconstrictor 
agent, which also stimulates the release of the salt- 
retaining hormone aldosterone from the adrenal cortex 
/7]. These actions elevate the blood pressure. The 
development of ACE inhibitors like captopril [8], 
enalapril and lisinopril [9] has made it possible to treat 
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hypertension in a new effective way. A characteristic of 
these inhibitors is that they have a proline residue in the 
C-terminal of their amino acid sequence. The beta- 
casomorphins, which also contain a proline residue, 
have already been shown to inhibit ACE activity 131. 
Since the hemorphins have the same N-terminal, Tyr- 
Pro, it is of interest to investigate their action on ACE 
activity, as well. 
The degradation of circulating angiotensin I to 
angiotensin II mainly occurs by the ACE bound to the 
vascular walls of the blood vessels in the lungs [lo, 111. 
Therefore, we investigated the stability of the synthesiz- 
ed peptides, LVV-hemorphin-6 and hemorphin-6 
towards membrane bound lung enzymes, including 
ACE. Incubations were performed with and without 
different protease inhibitors. The peptide fragments 
were separated by HPLC and analysed by mass spec- 
trometry. The influence of the hemorphins on ACE ac- 
tivity was examined by measuring their inhibitory effect 
on the hydrolysis of hippuryl-histidyl-leucine, a specific 
substrate for ACE activity. 
2. MATERIALS AND METHODS 
2.1. Materials 
The synthetic peptides used in this study were synthetized by Dr Cr. 
Lindeberg, Department of lmn~unolo&}~, University of Uppsata, 
Uppsala, Sweden. The ACE substrate hippuryl-histidyl-leuciile (hip- 
His-Leu) was from Cambridge Research Biochemicals and the ‘“C- 
labelled hip-His-Leu was purchased from NEN Products (Stockholm, 
Sweden). The protease inhibitors amastatin, phosphoramidon, 
EDTA, phenylmethylsuIphonyIfluoride (PMSF), parahydroxymer- 
curibenzoic acid (pHMR) and diisopropylfluorophosphare WFP) 
were from Sigma, and captopril was from Squibb. All other chemicals 
and solvents were of analytical grade from commercial sources. A 
Pharmacia/LKB system was used for rhe KP-HPLC separation. The 
instrument was equipped with a Silica gel C-IX column (Ultrapac 
Column TSK ODS 120 T, 4.6x250 mm, particle siLe 5.0 pm). 
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2.2. Enzytne preparation 
The enzyme c\tract !+a, prepared from human lung tissue, which 
was obtained at autopsy from patients \\ith no known lung disease. 
The time between death and autopsy did not exceed 38 h. \:ithin less 
than 1 h after autopsy the tissue \\a, stored at ~ 70°C. When prepar- 
ing the extract, 80 g of the tissue was thav.ed and homogcmzed in 5 
vola (400 ml) of 50 mM Tris-HCI buffer at pH 7.8. The solution \%as 
centrifuged in a Beckman J-2-21 centrifuge at 15OOOxg,,,,, for 40 
min. The pellet was bathed in 20 mhl Tris-HCI buffer, pH 7.8. mith 
subsequent centrifugation, 3 times. The membrane-bound enLyme 
wcrc solubiliLed by stirring the pellet material with buffer containing 
0.5”io Triton X-100 at 4°C for 16 h. After a final ccntrifugation, the 
enLyme containing tupernatant was stored in aliquor< at ~ 70°C. 
2.3. Inhibition studies 
The ACE activity wa5 monitored by measuring the hydrolysis 01 
hip-His-Leu. The enzyme extract was incubated, in polyethylene 
tubes with 100pM unlabelled and 15 000 cpm of “C-labelled hip-Hi,- 
Lcu (spec. act. 3.0 mCi/mmol) for 0. 20, 40, 80 or 120 min at 37”C, 
and buffered at pH 7.8 with 20 mhl Tris-HCI, all in a final volume of 
lOO;[l. Amastatin (20pcM) and phosphoramidon (10/M) were added 
to avoid degradation of the inhibiting peptides. For the inhibition 
assay, bradykinin, Tyr-Pro, hemorphin-4, hemorphin-6 and LVV- 
hernorphin-6, in a final concentration of lOO;chI, were used. The reac- 
tion was terminated bq- adding 100~1 of I h,l hydrochloric acid. To ex- 
tract the released product, hippuric acid, 2 ml ethylacetateiheptane 
(1.1) was added, vortexed for 15 5 and centrifuged for 10 min at 
500x g in a 2161 !vlidispin R centrifuge (LKB, Bromma, Sweden). A 
1 ml aliquot of the upper layer was removed for counting in a Packard 
liquid scintillation counter. 
2.4 Con version srudies 
Nanomolar concentration of the peptides, hcmorphin-6 and LVV- 
hemorphin-6, were’ incubated at 37°C in Eppendorf tubes with the en- 
zyme extract in the presence of various protease inhibitors, such as 
PhlSF (0.2 mhl), pHMB (0.2 mhl), EDTA (I .O mM). DFP (0.2 mhl), 
amastatin (20 pM), captopril (10 phi) and phosphoramidon (10 ,uh,l) 
in a final volume of 100 yl. The reaction mixture was buffered with 
20 mM Tris-HCI buffer at pH 7.8. The incubation time varied from 
I h up to 7 h. The reaction \vas terminated by adding 200,~l ice-cold 
ethanol, followed by centrifugarion in a Beckman Microfuge B for 5 
min. The supcrnatant \%as evaporated in a Savant Vat concentrator 
(Hicksville, NY, USA) prior to RP-HPLC separation of the generated 
products. 
2.5. Reversed phuse high perjormatw lrquid chromatography 
(RP-HPLC) 
The degradation product, were resolved on a Silica gel C-l R column 
with a nonlinear gradient of acctonitrile (ACN), containing 0.04% 
trifluoroacetic acid (TFA). The gradient was l5-60% of ACN solu- 
tion in 40 min and 60-X0’% in 10 min. The flow rate was 0.5 ml/min 
and fractions of 0.5 ml were collected and evaporated prior to mass 
spectromctry analysis. 
2.6. MUS spectrornetry anu!,sir 
The generated peptide fragments were analyzed by plasma desorp- 
tion mass spectrometry (PDMS) [12] on a Biolon 20 instrument (Ap- 
plied Biosystems AB, Sweden). 
3. RESULTS AND DISCUSSION 
Since the hemorphins might be formed in plasma 
during physiological or pathological degradation of 
hemoglobin, it is interesting to determine their action 
on ACE activity. Through this mechanism they may 
have a part in the regulation of blood pressure. Before 
studying the inhibitory effect on ACE activity of the 
hemorphins, the stability of the peptides in the enzyme 
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Table 1 
Hemorphins hydrolyred in citro by human lung extract 
Peptide Structure and cleavage point 
Hemorphin-6 
1 
Tcr-Pro-Trp-Thr-Gln-hre 
4 1. 
LVV-Hemorphln-6 Leu-Vnl-Val-Tqr-Pro-Trp-Thr-C;ln-Arg 
extract was examined. When hemorphin-6 was in- 
cubated with the lung enzyme extract, the Thr-Gln 
bond was cleaved and the hemorphin-4 fragment was 
formed (Table I, Fig. 1). The hydrolysis was inhibited 
by EDTA and phosphoramidon, but was not affected 
by any other of the enzyme inhibitors used (see Section 
2.4). This indicates that a thermolysin-like metalloen- 
dopeptidase (enkephalinase or EC 3.4.24.11) [13], is 
responsible for the cleavage. The tetrapeptide, 
0 
aa 
33 
bb 
1 1 
/’ k 
10 20 3oA 
time min 
Fig. 1. HPLC separations of hemorphin-6 (l-3) and LVV- 
hemorphin-6 (4-6) and their degradation products after I, 3, and 7 h 
of incubation. The identity of the peptide fragments was confirmed 
b) mass \pectromerry. 
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Table 11 
ACE activity in the presence of bradykinin and hemorphin related 
peptides, all in 100 pM concentration 
Peptide Hippuric acid 
released 
pmol/40 min 
% inhibition 
Control 431.9 0 
Bradykinin 9.4 98 
Tyr-Pro 343.1 22 
Hemorphin-6 161.7 63 
LVV-Hemorphin-6 62.3 86 
hemorphin-4, was very stable and remained even after 
7 h of incubation (Fig. 1). 
The longer peptide, LVV-hemorphin-6, was in- 
cubated with the same enzyme extract and for the same 
incubation times. After 1 h, with no inhibitor present, 
Gln-Arg was released (Table I, Fig. 1). Continued in- 
cubation up to 7 h gave no further cleavage of the LVV- 
hemorphin-4 fragment. In the presence of phosphora- 
midon, there was no change in the cleavage pattern, 
suggesting another enzyme responsible for the hydro- 
lysis of the Thr-Gin bond, than that cleaving 
hemorphin-6. None of the peptidase inhitors (captopril, 
amastatin, pHMB or PMSF) had any action on the 
cleavage pattern, while EDTA showed an unexpected 
effect. The hemorphin-4 fragment was released, thus 
indicating that the Val-Tyr bond is cleaved by an en- 
zyme sensitive to metal ions. Since hemorphin-6 was 
not seen when LVV-hemorphin-6 was incubated, the 
cleavage of the Thr-Gln bond is likely to precede the 
hydrolysis of the Val-Tyr bond. Accordingly, in the 
presence of phosphoramidon hemorphin-6 remained 
unconverted following one hour of incubation with the 
lung extract, whereas about 40% of LVV-hemorphin-6 
was converted to LVV-hemorphin-4. Both hemorphin-6 
and LVV-hemorphin-4 remained stable up to 7 h. 
All inhibitory experiments were performed in the 
presence of amastatin and phosphoramidon within a 
time course of 2 h. The most potent of the hemorphin 
related peptides assayed, appeared to be LVV-hemor- 
0 50 
Fig. 2. Time courses of the hydrolysis of hip-His-Leu by human lung 
ACE activity in the presence of bradykinin and hemorphin related 
peptides. 
phin-6, which inhibited the ACE activity by 86% (at 100 
PM) compared to 98% for bradykinin (100 PM) at 40 
min of incubation (Table II and Fig. 2). Compared to 
hemorphin-6, the LVV-hemorphin-6 was 1.4 times 
more potent and 4.0 times more potent than Tyr-Pro at 
the same concentration and incubation time. A definite 
inhibitory action was also seen by the hemorphin-4, 
which is the most stable metabolite. The fragment was 
prepared by enzyme incubation of hemorphin-6 and 
purified by HPLC and thereby the concentration could 
not be precise. 
When attempts were made to isolate LVV-hemor- 
phin-6 from plasma [3], it was not successful, probably 
because of its EDTA content. In this study we observed 
that EDTA enhanced the degradation of that very pep- 
tide, so it is quite possible that it occurs in plasma as 
well as in the pituitary. In conclusion, the most impor- 
tant hemorphin was LVV-hemorphin-6. Its stability 
was high towards the enzyme activities in the lung ex- 
tract and its inhibitory action on ACE activity was the 
strongest of the hemorphins assayed. Hemorphin-6 was 
less stable and appeared to be less potent in inhibiting 
the ACE activity. Further investigation needs to be 
done with the metabolites, LVV-hemorphin-4 and 
hemorphin-4. The natural concentrations of these pep- 
tides in plasma also need to be determined and thereby 
their possible importance in blood pressure regulation. 
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